REAl LIfe" Observational Study on the Effectiveness of Evusheld Prophylaxis Against SARS-CoV-2 Omicron Variants in Vaccine Non-responder Immunocompromised Patients

NCT07473986 · clinicaltrials.gov ↗

COMPLETED

Status

88

Enrollment

OTHER

Sponsor class

Conditions

SARS-CoV-2 Omicron Variants

Interventions

DRUG: Evusheld
OTHER: Control

Sponsor

Fondazione IRCCS Policlinico San Matteo di Pavia